US FDA declines to approve Schering-Plough's PegIntron for melanoma
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response on Schering-Plough's sBLA seeking an adjuvant melanoma indication for PegIntron (pegylated interferon alfa-2b).